By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

True North Therapeutics  

951 Gateway Boulevard

South San Francisco  Califonia  94080  U.S.A.
Phone: 650-872-4700 Fax: n/a


SEARCH JOBS




Key Statistics


Email: info@truenorth.com
Ownership: Private

Web Site: True North
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Biogen (BIIB) Spinoff Bioverativ (BIVV) Takes Out Bay Area's True North in $825 Million Deal 5/23/2017 5:42:59 AM
True North Therapeutics Appoints Biotechnology Commercial Executive Jeff Ajer To Its Board Of Directors 2/1/2017 8:24:04 AM
True North Therapeutics Presents Additional Data From An Ongoing Clinical Study Showing Normalization Of Hemoglobin Levels With TNT009 In Severely Anemic Cold Agglutinin Disease (CAD) Patients 12/5/2016 11:45:59 AM
Tiny Bay Area Biotech True North Therapeutics Bags $45 Million, Bringing the Total to $142 Million 10/18/2016 5:38:49 AM
True North Therapeutics Receives FDA Orphan Drug Designation For TNT009 For The Treatment Of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD) 10/13/2016 12:12:01 PM
True North Therapeutics Appoints Pamela M. Wapnick As Chief Financial Officer 8/2/2016 11:29:47 AM
True North Therapeutics To Present Clinical Data In Patients With Cold Agglutinin Disease (CAD) For Lead Product Candidate TNT009 6/13/2016 10:49:48 AM
True North Therapeutics ’s Lead Product Candidate, TNT009, Demonstrates High Response Rates And Rapid Onset Of Action In Interim Clinical Data In Patients With Cold Agglutinin Disease (CAD) 6/13/2016 10:23:19 AM
True North Therapeutics To Present Clinical Data In Patients With Cold Agglutinin Disease (CAD) For Lead Product Candidate TNT009 5/19/2016 12:21:58 PM
True North Therapeutics Launches COMPASS Registry To Advance Development Of New Therapeutics For Patients With Cold Agglutinin Disease (And Other Autoimmune Hemolytic Anemias) 3/8/2016 9:28:39 AM
123
//-->